NASDAQ:ZFGNZafgen Stock Price, Forecast & News

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN stock has increased by 1,135.1% and is now trading at $10.50.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Zafgen.

Zafgen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Zafgen.

Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings data on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.19).
View Zafgen's earnings history.

3 Wall Street analysts have issued 12-month price targets for Zafgen's shares. Their forecasts range from $0.78 to $0.78. On average, they expect Zafgen's stock price to reach $0.78 in the next twelve months. This suggests that the stock has a possible downside of 92.6%.
View analysts' price targets for Zafgen.

Headlines about ZFGN stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Zafgen earned a news impact score of 0.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Zafgen.

Zafgen saw a increase in short interest in January. As of January 15th, there was short interest totaling 823,200 shares, an increase of 58.1% from the December 31st total of 520,800 shares. Based on an average daily volume of 673,400 shares, the days-to-cover ratio is presently 1.2 days. Approximately 2.5% of the shares of the company are short sold.
View Zafgen's Short Interest.

Some companies that are related to Zafgen include Corcept Therapeutics (CORT), INDIVIOR PLC/S (INVVY), Seres Therapeutics (MCRB), Myovant Sciences (MYOV), Dicerna Pharmaceuticals (DRNA), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA), ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Zymeworks (ZYME), Akebia Therapeutics (AKBA), Zogenix (ZGNX) and Odonate Therapeutics (ODT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), SCYNEXIS (SCYX), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Fate Therapeutics (FATE) and Pfizer (PFE).

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZFGN stock can currently be purchased for approximately $10.50.

Zafgen has a market capitalization of $393.44 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe.

The official website for Zafgen is www.zafgen.com.

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]